MedMira (MedMira) Common Stock : $51.16 Mil (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira Common Stock?

MedMira's quarterly common stock declined from Jul. 2023 ($51.74 Mil) to Oct. 2023 ($49.85 Mil) but then increased from Oct. 2023 ($49.85 Mil) to Jan. 2024 ($51.16 Mil).

MedMira's annual common stock increased from Jul. 2021 ($51.00 Mil) to Jul. 2022 ($52.84 Mil) but then declined from Jul. 2022 ($52.84 Mil) to Jul. 2023 ($51.74 Mil).

MedMira Common Stock Historical Data

The historical data trend for MedMira's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Common Stock Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Common Stock

Get a 7-Day Free Trial

48.40

46.99

51.00

52.84

51.74

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Common Stock	Get a 7-Day Free Trial															50.92	50.69	51.74	49.85	51.16

MedMira Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.